Phase II HCC Adjuvant Study in 37 Patients: 1-Year RFS 59.7%, Median RFS 15.6 Months
The phase II ALTER-H006 study published in Nature Communications evaluated adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma. The study enrolled 37 patients, with a median follow-up of 12.6 months.
The 1-year recurrence-free survival rate was 59.7%, and median recurrence-free survival was 15.6 months. The 1-year overall survival rate was 91.7%, with median overall survival not reached. The longest recurrence-free duration was 25.9 months.
Grade 3 or higher treatment-related adverse events occurred in 45.9% of patients, most commonly hypertension, and no treatment-related deaths occurred. The authors said the regimen is a feasible option warranting confirmation in large-scale randomized trials.
Source: Nature Communications
Published by GSM · USA (original Chinese edition)
Photo: 肝细胞癌的病理切片图像。照片：Ed Uthman，CC BY 2.0，经 Wikimedia Commons / Hepatocellular carcinoma pathology. Photo: Ed Uthman, CC BY 2.0, via Wikimedia Commons
